PubRank

Alan Ashworth

Author PubWeight™ 427.31‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005 26.32
2 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009 24.75
3 Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004 10.31
4 Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013 8.24
5 Translating cancer research into targeted therapeutics. Nature 2010 7.33
6 Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010 6.88
7 Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010 6.42
8 Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006 6.28
9 CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003 6.00
10 Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008 5.85
11 DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015 5.39
12 The DNA damage response and cancer therapy. Nature 2012 5.25
13 CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res 2005 4.79
14 Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009 4.68
15 BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010 4.66
16 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013 4.35
17 Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 2005 4.31
18 FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010 3.89
19 Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 2013 3.81
20 Stem cells and breast cancer: A field in transit. Nat Rev Cancer 2003 3.47
21 Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 2006 3.24
22 Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012 3.20
23 Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst 2011 3.05
24 A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008 2.95
25 Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 2012 2.66
26 Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 2002 2.63
27 Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012 2.53
28 Functional viability profiles of breast cancer. Cancer Discov 2011 2.44
29 Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007 2.43
30 Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A 2007 2.41
31 Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008 2.40
32 Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012 2.38
33 A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res 2010 2.37
34 The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 2008 2.27
35 Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet 2013 2.24
36 Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009 2.17
37 FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006 2.15
38 Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab 2005 2.04
39 Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta 2004 2.04
40 Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res 2006 2.03
41 Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011 1.99
42 The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002 1.97
43 A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010 1.96
44 Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013 1.94
45 LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells. Eur J Immunol 2010 1.94
46 Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 2013 1.93
47 An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2009 1.93
48 Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res 2011 1.90
49 Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008 1.90
50 MAP kinase phosphatases. Genome Biol 2002 1.88
51 Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 2011 1.86
52 A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. EMBO J 2003 1.82
53 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res 2012 1.81
54 The relationship between obesity and exposure to light at night: cross-sectional analyses of over 100,000 women in the Breakthrough Generations Study. Am J Epidemiol 2014 1.80
55 Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 2011 1.79
56 Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010 1.79
57 BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005 1.76
58 Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005 1.75
59 Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 2007 1.74
60 Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet 2004 1.73
61 DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008 1.73
62 Pregnancy and the risk of breast cancer. Endocr Relat Cancer 2007 1.72
63 A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008 1.70
64 Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J 2009 1.68
65 Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009 1.68
66 Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011 1.65
67 PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010 1.64
68 Familial concordance for age at natural menopause: results from the Breakthrough Generations Study. Menopause 2011 1.63
69 Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov 2012 1.62
70 Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol 2010 1.62
71 Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007 1.61
72 Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006 1.59
73 Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011 1.56
74 High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. Genome Biol 2011 1.53
75 DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 2010 1.52
76 Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res 2012 1.52
77 DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep 2004 1.52
78 Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics 2005 1.52
79 A genome-wide association study of early menopause and the combined impact of identified variants. Hum Mol Genet 2013 1.50
80 Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep 2009 1.50
81 Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009 1.49
82 PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 2009 1.49
83 BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 2013 1.47
84 Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010 1.47
85 Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med 2014 1.47
86 LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 2010 1.47
87 Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005 1.47
88 Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst 2011 1.45
89 Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1. Oncogene 2003 1.43
90 Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci U S A 2011 1.42
91 Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005 1.40
92 Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 2007 1.40
93 Signalling pathways implicated in early mammary gland morphogenesis and breast cancer. PLoS Genet 2006 1.40
94 Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet 2013 1.39
95 A novel short splice variant of the tumour suppressor LKB1 is required for spermiogenesis. Biochem J 2008 1.38
96 Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008 1.35
97 Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Lab Invest 2007 1.35
98 Searching for synthetic lethality in cancer. Curr Opin Genet Dev 2011 1.34
99 p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep 2006 1.34
100 Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One 2009 1.33
101 Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006 1.32
102 Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res 2008 1.32
103 Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011 1.31
104 A targeted deletion in the endocytic receptor gene Endo180 results in a defect in collagen uptake. EMBO Rep 2003 1.31
105 Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007 1.31
106 FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011 1.29
107 Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol 2006 1.28
108 Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction. Arch Dermatol 2009 1.28
109 Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 2011 1.27
110 The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res 2006 1.26
111 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat 2012 1.26
112 Gene expression following ionising radiation: identification of biomarkers for dose estimation and prediction of individual response. Int J Radiat Biol 2010 1.26
113 ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008 1.25
114 Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010 1.25
115 Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells. Breast Cancer Res 2009 1.25
116 The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012 1.23
117 A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 2009 1.23
118 Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 2013 1.22
119 Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation. Nucleic Acids Res 2012 1.22
120 Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 2013 1.20
121 Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 2005 1.20
122 Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 2014 1.19
123 Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet 2003 1.19
124 Lkb1 deficiency alters goblet and paneth cell differentiation in the small intestine. PLoS One 2009 1.18
125 Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010 1.17
126 Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS One 2012 1.13
127 Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res 2010 1.13
128 Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev 2009 1.13
129 Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2006 1.13
130 Biology-driven cancer drug development: back to the future. BMC Biol 2010 1.12
131 A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One 2013 1.11
132 Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res 2006 1.11
133 Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nat Genet 2012 1.10
134 LKB1 kinase: master and commander of metabolism and polarity. Curr Biol 2004 1.10
135 Common genetic variants are significant risk factors for early menopause: results from the Breakthrough Generations Study. Hum Mol Genet 2010 1.10
136 Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res 2011 1.09
137 Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 2013 1.09
138 Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther 2006 1.08
139 Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol Med 2010 1.08
140 LKB1 is required for hepatic bile acid transport and canalicular membrane integrity in mice. Biochem J 2011 1.08
141 Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification. Genes Dev 2005 1.08
142 Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol 2009 1.08
143 RAD51, BRCA2 and DNA repair: a partial resolution. Nat Struct Mol Biol 2007 1.07
144 An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. Cancer Discov 2014 1.07
145 CYP3A variation, premenopausal estrone levels, and breast cancer risk. J Natl Cancer Inst 2012 1.06
146 Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008 1.05
147 Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. Breast Cancer Res Treat 2012 1.03
148 Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells 2012 1.03
149 BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 2005 1.02
150 Deletion of Lkb1 in pro-opiomelanocortin neurons impairs peripheral glucose homeostasis in mice. Diabetes 2011 1.02
151 Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer 2009 1.02
152 Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert Rev Anticancer Ther 2011 1.02
153 Genomic instability and the selection of treatments for cancer. J Pathol 2010 1.02
154 Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes Chromosomes Cancer 2011 1.01
155 A modified method for whole exome resequencing from minimal amounts of starting DNA. PLoS One 2012 1.00
156 A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet 2013 1.00
157 Receptor and secreted targets of Wnt-1/beta-catenin signalling in mouse mammary epithelial cells. BMC Cancer 2005 0.99
158 Multiple Hodgkin lymphoma-associated loci within the HLA region at chromosome 6p21.3. Blood 2011 0.99
159 Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res 2013 0.99
160 Structural analysis of the chicken BRCA2 gene facilitates identification of functional domains and disease causing mutations. Hum Mol Genet 2002 0.99
161 Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov 2013 0.98
162 Functional analysis of Drosophila melanogaster BRCA2 in DNA repair. DNA Repair (Amst) 2007 0.97
163 Body mass index, exercise, and other lifestyle factors in relation to age at natural menopause: analyses from the breakthrough generations study. Am J Epidemiol 2012 0.97
164 Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study. Breast Cancer Res 2014 0.97
165 Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 2012 0.96
166 Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. Clin Cancer Res 2008 0.96
167 Secular trends in age at menarche in women in the UK born 1908-93: results from the Breakthrough Generations Study. Paediatr Perinat Epidemiol 2011 0.96
168 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2012 0.95
169 Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation. J Pathol 2009 0.95
170 AXL and acquired resistance to EGFR inhibitors. Nat Genet 2012 0.95
171 The genomic landscape of oesophagogastric junctional adenocarcinoma. J Pathol 2013 0.95
172 Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy. Hum Mol Genet 2008 0.95
173 APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. EMBO J 2012 0.94
174 Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. BMC Med Genomics 2011 0.94
175 Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol Med 2012 0.94
176 Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol 2010 0.93
177 Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells. J Clin Pathol 2006 0.93
178 Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation. EMBO Rep 2002 0.93
179 PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol 2010 0.92
180 Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in men. PLoS Genet 2011 0.92
181 Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. PLoS One 2011 0.91
182 Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression. J Pathol 2011 0.91
183 Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev 2010 0.91
184 Neuregulin3 alters cell fate in the epidermis and mammary gland. BMC Dev Biol 2007 0.90
185 Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. Int J Cancer 2014 0.90
186 Identification of miRNA modulators to PARP inhibitor response. DNA Repair (Amst) 2013 0.90
187 Genomic characterisation of acral melanoma cell lines. Pigment Cell Melanoma Res 2012 0.89
188 Familial concordance for age at menarche: analyses from the Breakthrough Generations Study. Paediatr Perinat Epidemiol 2011 0.89
189 High-throughput RNAi screening reveals novel regulators of telomerase. Cancer Res 2011 0.89
190 DNA amplifications in breast cancer: genotypic-phenotypic correlations. Future Oncol 2010 0.89
191 Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers. Breast Cancer Res 2007 0.89
192 LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. Anticancer Res 2007 0.88
193 Can genetic testing guide treatment in breast cancer? Eur J Cancer 2008 0.88
194 Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet 2010 0.88
195 Functional characterization of EMSY gene amplification in human cancers. J Pathol 2011 0.88
196 Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma. Histopathology 2009 0.87
197 Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ERalpha) in response to therapeutic radiation. J Pathol 2009 0.87
198 Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. Genet Epidemiol 2013 0.86
199 Phenotypic effects of heterozygosity for a BRCA2 mutation. Hum Mol Genet 2003 0.86
200 BRCA1 and stem cells: tumour typecasting. Nat Cell Biol 2008 0.85
201 Biomarkers of PARP inhibitor sensitivity. Breast Cancer Res Treat 2011 0.84
202 IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. Br J Haematol 2009 0.84
203 Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity. Oncogene 2003 0.83
204 Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. Endocr Relat Cancer 2013 0.83
205 Dynamic expression of Erbb pathway members during early mammary gland morphogenesis. J Invest Dermatol 2007 0.82
206 Effect of delays in processing blood samples on measured endogenous plasma sex hormone levels in women. Cancer Epidemiol Biomarkers Prev 2007 0.82
207 X-chromosome inactivation: X marks the spot for BRCA1. Curr Biol 2003 0.81
208 Genomics: Comparisons across cancers. Nature 2013 0.81
209 Intestinal renin-angiotensin system is stimulated after deletion of Lkb1. Gut 2011 0.81
210 Refocusing on BRCA1. Nat Cell Biol 2004 0.81
211 Reversion to sinus rhythm after induction of general anaesthesia. Br J Hosp Med (Lond) 2010 0.81
212 Biomedicine. D-Day for BRCA2. Science 2002 0.80
213 Retroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell line. BMC Mol Biol 2002 0.80
214 Bringing DNA repair in tumors into focus. Clin Cancer Res 2009 0.80
215 Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss. Genes Chromosomes Cancer 2006 0.80
216 Changes in estradiol and testosterone levels in postmenopausal women after changes in body mass index. J Clin Endocrinol Metab 2013 0.80
217 Differential effects of stress stimuli on a JNK-inactivating phosphatase. Oncogene 2002 0.79
218 Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 2007 0.79
219 NLK is a novel therapeutic target for PTEN deficient tumour cells. PLoS One 2012 0.79
220 Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology. Breast Cancer Res Treat 2011 0.79
221 FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma. Blood 2011 0.78
222 X-linked microtubule-associated protein, Mid1, regulates axon development. Proc Natl Acad Sci U S A 2013 0.78
223 BRCA2 in meiosis: turning over a new leaf. Trends Cell Biol 2004 0.78
224 An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence. BMC Genomics 2011 0.78
225 Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation. Leuk Lymphoma 2008 0.78
226 Close relatives or distant cousins? Lancet Oncol 2003 0.78
227 Dissecting resistance to endocrine therapy in breast cancer. Cell Cycle 2008 0.77
228 The promise of combining inhibition of PI3K and PARP as cancer therapy. Cancer Discov 2012 0.77
229 Familial concordance for height and its components: analyses from the Breakthrough Generations Study. Am J Hum Biol 2011 0.77
230 A new gene on the X involved in Fanconi anemia. Nat Genet 2004 0.75
231 Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS One 2017 0.75
232 CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. Carcinogenesis 2009 0.75
233 Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase. Mol Cancer Ther 2013 0.75
234 Ultrasound-guided arterial cannulation. Eur J Anaesthesiol 2010 0.75
235 Reproducibility of estradiol and testosterone levels in postmenopausal women over 5 years: results from the breakthrough generations study. Am J Epidemiol 2014 0.75
236 Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS One 2016 0.75
237 An interview with Pharmacogenomics for the breast cancer special focus issue. Pharmacogenomics 2012 0.75
238 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res 2006 0.75
239 New biology of the oestrogen receptor. Lancet 2003 0.75
240 Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep 2017 0.75
241 Regional anaesthesia: awake or asleep? Br J Hosp Med (Lond) 2011 0.75